» Articles » PMID: 24130897

Rapid in Vitro Derivation of Endothelium Directly from Human Cancer Cells

Overview
Journal PLoS One
Date 2013 Oct 17
PMID 24130897
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The development of an independent blood supply by a tumor is essential for maintaining growth beyond a certain limited size and for providing a portal for metastatic dissemination. Host-derived endothelial cells (ECs) residing in and compromising the tumor vasculature originate via distinct processes known as sprouting angiogenesis and vasculogenesis. More recently ECs originating directly from the tumor cells themselves have been described although the basis for this phenomenon remains poorly understood. Here we describe in vitro conditions that allow lung and ovarian cancer cells to undergo a rapid and efficient transition into ECs that are indistinguishable from those obtained in vivo. A variety of methods were used to establish that the acquired phenotypes and behaviors of these tumor-derived ECs (TDECs) closely resemble those of authentic ECs. Xenografts arising from co-inoculated in vitro-derived TDECs and tumor cells were also more highly vascularized than control tumors; moreover, their blood vessels were on average larger and frequently contained admixtures of host-derived ECs and TDECs derived from the initial inoculum. These results demonstrate that cancer cells can be manipulated under well-defined in vitro conditions to initiate a tumor cell-to-EC transition that is largely cell-autonomous, highly efficient and closely mimics the in vivo process. These studies provide a suitable means by which to identify and perhaps modify the earliest steps in TDEC generation.

Citing Articles

Origin of Cancer: Cell work is the Key to Understanding Cancer Initiation and Progression.

Hanselmann R, Welter C Front Cell Dev Biol. 2022; 10:787995.

PMID: 35300431 PMC: 8921603. DOI: 10.3389/fcell.2022.787995.

References
1.
Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

2.
Sharma S, Sharma M, Sarkar C . Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology. 2005; 46(5):481-9. DOI: 10.1111/j.1365-2559.2005.02142.x. View

3.
Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros P . Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol. 2003; 13(2):133-43. PMC: 8095831. DOI: 10.1111/j.1750-3639.2003.tb00013.x. View

4.
Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O . Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004; 351(3):250-9. DOI: 10.1056/NEJMoa033153. View

5.
Aghi M, Cohen K, Klein R, Scadden D, Chiocca E . Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 2006; 66(18):9054-64. DOI: 10.1158/0008-5472.CAN-05-3759. View